Product
Help
Pricing
About
Jobs
Log in
Get started
Keyword
Add to collection
AT-101
Description:
An investigational anticancer compound derived from gossypol that can promote apoptosis and inhibit tumor-associated signaling pathways.
Primary topic:
Cell death mechanisms and regulation (27%)
Related topics:
Cell death mechanisms and regulation (27%),
Prostate Cancer Treatment and Research (17%)
OpenAlex ID:
keywords/at-101
Bcl-2 Inhibitors: Targeting Mitochondrial Apoptotic Pathways in Cancer Therapy
2009
·
Min H. Kang
, C. Patrick Reynolds
·
Clinical Cancer Research
·
1,125
PDF
An Open-Label, Multicenter, Phase I/II Study of Single-Agent AT-101 in Men with Castrate-Resistant Prostate Cancer
2009
·
Glenn Liu
, W. Kevin Kelly
, et al.
·
Clinical Cancer Research
·
190
PDF
A Phase II Study of AT-101 (Gossypol) in Chemotherapy-Sensitive Recurrent Extensive-Stage Small Cell Lung Cancer
2011
·
Maria Q. Baggstrom
, Yingwei Qi
, et al.
·
Journal of Thoracic Oncology
·
171
PDF
AT-101 induces apoptosis in CLL B cells and overcomes stromal cell–mediated Mcl-1 induction and drug resistance
2008
·
Kumudha Balakrishnan
, Jan A. Burger
, et al.
·
Blood
·
158
PDF
Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma
2008
·
Luca Paoluzzi
, Mithat Gonen
, et al.
·
Blood
·
158
PDF
Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer
2011
·
G. Sonpavde
, V. Matveev
, et al.
·
Annals of Oncology
·
155
AT 101 induces early mitochondrial dysfunction and HMOX1 (heme oxygenase 1) to trigger mitophagic cell death in glioma cells
2018
·
Nina Meyer
, Svenja Zielke
, et al.
·
Autophagy
·
138
PDF
Double-Blind, Placebo-Controlled, Randomized Phase 2 Study of the Proapoptotic Agent AT-101 Plus Docetaxel, in Second-Line Non-small Cell Lung Cancer
2011
·
Neal Ready
, Nina A. Karaseva
, et al.
·
Journal of Thoracic Oncology
·
101
Mcl1 downregulation sensitizes neuroblastoma to cytotoxic chemotherapy and small molecule Bcl2-family antagonists
2009
·
Brian J. Lestini
, Kelly C. Goldsmith
, et al.
·
Cancer Biology & Therapy
·
100
PDF
BH3-only protein BIM: An emerging target in chemotherapy
2017
·
Shatrunajay Shukla
, Sugandh Saxena
, et al.
·
European Journal of Cell Biology
·
94
Phase I/II Study of AT-101 with Topotecan in Relapsed and Refractory Small Cell Lung Cancer
2010
·
Rebecca Suk Heist
, Jerry Fain
, et al.
·
Journal of Thoracic Oncology
·
88
PDF
Chemoresistance is associated with increased cytoprotective autophagy and diminished apoptosis in bladder cancer cells treated with the BH3 mimetic (−)-Gossypol (AT-101)
2015
·
Jens Mani
, Stefan Vallo
, et al.
·
BMC Cancer
·
82
PDF
Systematic Review of Gossypol/AT-101 in Cancer Clinical Trials
2022
·
Olga Renner
, Mascha Mayer
, et al.
·
Pharmaceuticals
·
81
PDF
Interference with the HSF1/HSP70/BAG3 Pathway Primes Glioma Cells to Matrix Detachment and BH3 Mimetic–Induced Apoptosis
2017
·
Patrick Antonietti
, Benedikt Linder
, et al.
·
Molecular Cancer Therapeutics
·
77
Anti-cancer drug discovery and development: Bcl-2 family small molecule inhibitors
2012
·
Qiang Liu
, Hong-Gang Wang
·
Communicative & Integrative Biology
·
67
PDF
Targeting cancer stem cells with a pan-BCL-2 inhibitor in preclinical and clinical settings in patients with gastroesophageal carcinoma
2021
·
Shumei Song
, Qiongrong Chen
, et al.
·
Gut
·
66
AT-101, a small molecule inhibitor of anti-apoptotic Bcl-2 family members, activates the SAPK/JNK pathway and enhances radiation-induced apoptosis
2009
·
Shuraila F Zerp
, Rianne Stoter
, et al.
·
Radiation Oncology
·
64
PDF
R-(-)−gossypol (AT-101) activates programmed cell death in multiple myeloma cells
2008
·
Michael P. Kline
, S. Vincent Rajkumar
, et al.
·
Experimental Hematology
·
63
PDF
BH3 response profiles from neuroblastoma mitochondria predict activity of small molecule Bcl-2 family antagonists
2009
·
K C Goldsmith
, B J Lestini
, et al.
·
Cell Death and Differentiation
·
58
In Vivo Evaluation of AT-101 (R-(—)-Gossypol Acetic Acid) in Androgen-Independent Growth of VCaP Prostate Cancer Cells in Combination with Surgical Castration
2007
·
Robert D. Loberg
, Natalie McGregor
, et al.
·
Neoplasia
·
58
PDF
A Phase II Study of AT-101 to Overcome Bcl-2–Mediated Resistance to Androgen Deprivation Therapy in Patients With Newly Diagnosed Castration-Sensitive Metastatic Prostate Cancer
2015
·
Mark N. Stein
, Maha Hussain
, et al.
·
Clinical Genitourinary Cancer
·
54
PDF
AT-101, a Pan-Bcl-2 Inhibitor, Leads to Radiosensitization of Non-small Cell Lung Cancer
2010
·
Luigi Moretti
, Bo Li
, et al.
·
Journal of Thoracic Oncology
·
54
Targeting anti-apoptotic Bcl-2 by AT-101 to increase radiation efficacy: data from in vitro and clinical pharmacokinetic studies in head and neck cancer
2015
·
Shuraila F. Zerp
, T. Rianne Stoter
, et al.
·
Radiation Oncology
·
52
PDF
Radiographic progression by Prostate Cancer Working Group ( PCWG )‐2 criteria as an intermediate endpoint for drug development in metastatic castration‐resistant prostate cancer
2014
·
Guru Sonpavde
, Gregory R. Pond
, et al.
·
British Journal of Urology
·
51
PDF
A phase I study of AT-101 with cisplatin and etoposide in patients with advanced solid tumors with an expanded cohort in extensive-stage small cell lung cancer
2013
·
William R. Schelman
, Tabraiz A. Mohammed
, et al.
·
Investigational New Drugs
·
51
Show more works
View as search
Works count:
154
Citation count:
4,691
Year
Topic
Type